

Harry Sokol

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3791009/harry-sokol-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

230
papers

19,301
citations

64
h-index

136
g-index

275
ext. papers

25,596
ext. citations

9.3
avg, IF

7.09
L-index

#	Paper	IF	Citations
230	AhR/IL-22 pathway as new target for the treatment of post-infectious irritable bowel syndrome symptoms.. <i>Gut Microbes</i> , 2022 , 14, 2022997	8.8	2
229	Patient knowledge of gut microbiota and acceptability of fecal microbiota transplantation in various diseases.. <i>Neurogastroenterology and Motility</i> , 2022 , e14320	4	1
228	Long-term diosmectite use does not alter the gut microbiota in adults with chronic diarrhea.. <i>BMC Microbiology</i> , 2022 , 22, 54	4.5	
227	Validation of the performance of A1HPV6, a triage blood test for the early diagnosis and prognosis of SARS-CoV-2 infection. 2022 ,		1
226	Microbiota in 'neuroinflammation' and 'synaptic dysfunction': a focus on Alzheimer's disease.. <i>Molecular Neurodegeneration</i> , 2022 , 17, 19	19	5
225	Alteration of the gut microbiota following SARS-CoV-2 infection correlates with disease severity in hamsters.. <i>Gut Microbes</i> , 2022 , 14, 2018900	8.8	7
224	SER-109 for Recurrent Clostridioides difficile Infection.. <i>New England Journal of Medicine</i> , 2022 , 386, 1956-1957	59.2	
223	A Scoring System to Determine Patients' Risk of Colectomy Within 1 Year After Hospital Admission for Acute Severe Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1602-1610.e1	6.9	8
222	Circulating bile acids concentration is predictive of coronary artery disease in human. <i>Scientific Reports</i> , 2021 , 11, 22661	4.9	2
221	Reporting guidelines for human microbiome research: the STORMS checklist. <i>Nature Medicine</i> , 2021 , 27, 1885-1892	50.5	19
220	Vasoactive intestinal peptide promotes host defense against enteric pathogens by modulating the recruitment of group 3 innate lymphoid cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	5
219	PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab + Tremelimumab in second-line of patients with advanced gastric cancer. <i>Digestive and Liver Disease</i> , 2021 , 53, 420-426	3.3	4
218	SARS-CoV-2 vaccines and donor recruitment for FMT. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 264-266	18.8	3
217	Arthrose et microbiote intestinal. <i>Revue Du Rhumatisme Monographies</i> , 2021 , 88, 92-96	0	
216	Recipient factors in faecal microbiota transplantation: one stool does not fit all. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 , 18, 503-513	24.2	24
215	Impact of gut fungal and bacterial communities on the outcome of allogeneic hematopoietic cell transplantation. <i>Mucosal Immunology</i> , 2021 , 14, 1127-1132	9.2	1
214	Gut microbiota-derived short-chain fatty acids regulate IL-17 production by mouse and human intestinal T _H 17 cells. <i>Cell Reports</i> , 2021 , 36, 109332	10.6	18

213	Infections in Patients with Chronic Granulomatous Disease Treated with Tumor Necrosis Factor Alpha Blockers for Inflammatory Complications. <i>Journal of Clinical Immunology</i> , 2021 , 41, 185-193	5.7	4
212	A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group. <i>United European Gastroenterology Journal</i> , 2021 , 9, 229-247	5.3	19
211	Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury. <i>Gut</i> , 2021 , 70, 1299-1308	19.2	23
210	Tryptophan Metabolism as a Pharmacological Target. <i>Trends in Pharmacological Sciences</i> , 2021 , 42, 60-73	13.2	31
209	Gut microbiota-derived metabolites as central regulators in metabolic disorders. <i>Gut</i> , 2021 , 70, 1174-1182	12.2	101
208	Tryptophan metabolites get the gut moving. <i>Cell Host and Microbe</i> , 2021 , 29, 145-147	23.4	6
207	The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey. <i>Lancet Regional Health - Europe, The</i> , 2021 , 9, 100181		5
206	Immune-mediated inflammatory diseases and nutrition: results from an online survey on patients' practices and perceptions. <i>BMC Nutrition</i> , 2021 , 7, 38	2.5	2
205	Blockage of bacterial FimH prevents mucosal inflammation associated with Crohn's disease. <i>Microbiome</i> , 2021 , 9, 176	16.6	5
204	Postbiotics - when simplification fails to clarify. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 , 18, 825-826	24.2	15
203	Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial. <i>Digestive and Liver Disease</i> , 2021 , 53, 1254-1259	3.3	2
202	SARS-CoV-2 infection in nonhuman primates alters the composition and functional activity of the gut microbiota. <i>Gut Microbes</i> , 2021 , 13, 1-19	8.8	36
201	Increased risk of permanent stoma in Crohn's disease associated with hidradenitis suppurativa: a case-control study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 303-310	6.1	0
200	Human microbial metabolite mimicry as a strategy to expand the chemical space of potential drugs. <i>Drug Discovery Today</i> , 2020 , 25, 1575-1579	8.8	0
199	Impact of fecal microbiota transplantation on chronic recurrent pouchitis in ulcerative colitis with ileo-anal anastomosis: study protocol for a prospective, multicenter, double-blind, randomized, controlled trial. <i>Trials</i> , 2020 , 21, 455	2.8	2
198	Donated stool for faecal microbiota transplantation is not a drug, but guidance and regulation are needed. <i>United European Gastroenterology Journal</i> , 2020 , 8, 353-354	5.3	
197	Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 430-432	18.8	82
196	Ozone-Induced Aryl Hydrocarbon Receptor Activation Controls Lung Inflammation via Interleukin-22 Modulation. <i>Frontiers in Immunology</i> , 2020 , 11, 144	8.4	18

195	Fecal microbiota transplantation in gastrointestinal disorders: time for precision medicine. <i>Genome Medicine</i> , 2020 , 12, 58	14.4	14
194	Potential Causes and Consequences of Gastrointestinal Disorders during a SARS-CoV-2 Infection. <i>Cell Reports</i> , 2020 , 32, 107915	10.6	68
193	Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. <i>Gut</i> , 2020 , 69, 1555-1563	19.2	57
192	Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 223-237	24.2	318
191	Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, 896-903	1.5	4
190	Fecal microbiota transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study. <i>Microbiome</i> , 2020 , 8, 12	16.6	89
189	Dendritic cell-derived hepcidin sequesters iron from the microbiota to promote mucosal healing. <i>Science</i> , 2020 , 368, 186-189	33.3	46
188	Gut microbiome alterations in anti-NMDA receptor encephalitis: caveats for result interpretation. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 153-154	5.3	1
187	The enemy from within: a prophage of <i>Roseburia intestinalis</i> systematically turns lytic in the mouse gut, driving bacterial adaptation by CRISPR spacer acquisition. <i>ISME Journal</i> , 2020 , 14, 771-787	11.9	20
186	Impact of Aphthous Colitis at Diagnosis on Crohn's Disease Outcomes. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, 342-350	1.5	0
185	Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines. <i>United European Gastroenterology Journal</i> , 2020 , 8, 303-313	5.3	58
184	A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 553-564	6.1	13
183	Butyrate mediates anti-inflammatory effects of in intestinal epithelial cells through. <i>Gut Microbes</i> , 2020 , 12, 1-16	8.8	22
182	Tofacitinib treatment alters mucosal immunity and gut microbiota during experimental arthritis. <i>Clinical and Translational Medicine</i> , 2020 , 10, e163	5.7	0
181	Drug Mimicry: Promiscuous Receptors PXR and AhR, and Microbial Metabolite Interactions in the Intestine. <i>Trends in Pharmacological Sciences</i> , 2020 , 41, 900-908	13.2	14
180	Aryl hydrocarbon receptor ligand production by the gut microbiota is decreased in celiac disease leading to intestinal inflammation. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	44
179	Mechanisms underpinning the efficacy of faecal microbiota transplantation in treating gastrointestinal disease. <i>Therapeutic Advances in Gastroenterology</i> , 2020 , 13, 1756284820946904	4.7	10
178	The Gut Microbiota at the Service of Immunometabolism. <i>Cell Metabolism</i> , 2020 , 32, 514-523	24.6	50

177	Linking Strain Engraftment in Fecal Microbiota Transplantation With Maintenance of Remission in Crohn's Disease. <i>Gastroenterology</i> , 2020 , 159, 2193-2202.e5	13.3	16
176	Glycans as Immune Checkpoints: Removal of Branched N-glycans Enhances Immune Recognition Preventing Cancer Progression. <i>Cancer Immunology Research</i> , 2020 , 8, 1407-1425	12.5	10
175	Antibiotics: a trigger for inflammatory bowel disease?. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 956-957	18.8	2
174	Association Between Microscopic Lesions at Ileal Resection Margin and Recurrence After Surgery in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 141-149.e2	6.9	10
173	Prominence of ileal mucosa-associated microbiota to predict postoperative endoscopic recurrence in Crohn's disease. <i>Gut</i> , 2020 , 69, 462-472	19.2	44
172	Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis. <i>Gut</i> , 2020 , 69, 92-102	19.2	62
171	Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 620-627.e1	6.9	7
170	Nancy Index Scores of Chronic Inflammatory Bowel Disease Activity Associate With Development of Colorectal Neoplasia. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 150-157.e1	6.9	7
169	Gut microbiota in PSC: From association to possible causality. Commentary to "Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis" by Nakamoto et al., Nature Microbiology, January 2019. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020 , 44, 123-125	2.4	2
168	Skews Human DC to Prime IL10-Producing T Cells Through TLR2/6/JNK Signaling and IL-10, IL-27, CD39, and IDO-1 Induction. <i>Frontiers in Immunology</i> , 2019 , 10, 143	8.4	45
167	Fecal Microbiota Transplantation for Ulcerative Colitis. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 2240	27.4	2
166	Genetic effects on the commensal microbiota in inflammatory bowel disease patients. <i>PLoS Genetics</i> , 2019 , 15, e1008018	6	24
165	Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 773-783	27.4	75
164	Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria. <i>Haematologica</i> , 2019 , 104, 1682-1688	6.6	60
163	T cell clonal expansions in ileal Crohn's disease are associated with smoking behaviour and postoperative recurrence. <i>Gut</i> , 2019 , 68, 1961-1970	19.2	19
162	Specific changes in faecal microbiota are associated with familial Mediterranean fever. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1398-1404	2.4	5
161	Baseline microbiota composition modulates antibiotic-mediated effects on the gut microbiota and host. <i>Microbiome</i> , 2019 , 7, 111	16.6	24
160	Oral delivery of pancreatitis-associated protein by <i>Lactococcus lactis</i> displays protective effects in dinitro-benzenesulfonic-acid-induced colitis model and is able to modulate the composition of the microbiota. <i>Environmental Microbiology</i> , 2019 , 21, 4020-4031	5.2	8

159	A necessary discussion after transmission of multidrug-resistant organisms through faecal microbiota transplantations. <i>Lancet Infectious Diseases, The</i> , 2019 , 19, 1161-1162	25.5	6
158	The Gut Microbiome in Inflammatory Bowel Disease 2019 , 347-377		
157	Impact of Gut Mycobacteria Composition on Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2019 , 134, 194-194	2.2	
156	The gut mycobacteria: insights into analysis, environmental interactions and role in gastrointestinal diseases. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 331-345	24.2	128
155	Stool for fecal microbiota transplantation should be classified as a transplant product and not as a drug. <i>United European Gastroenterology Journal</i> , 2019 , 7, 1408-1410	5.3	8
154	International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. <i>Gut</i> , 2019 , 68, 2111-2121	19.2	169
153	Intestinal dysbiosis in inflammatory bowel disease associated with primary immunodeficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 143, 775-778.e6	11.5	15
152	Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice. <i>Gut</i> , 2019 , 68, 1504-1515	19.2	100
151	Validation of a global quantitative analysis methodology of tryptophan metabolites in mice using LC-MS. <i>Talanta</i> , 2019 , 195, 593-598	6.2	14
150	The regenerating family member 3 β instigates IL-17A-mediated neutrophil recruitment downstream of NOD1/2 signalling for controlling colonisation resistance independently of microbiota community structure. <i>Gut</i> , 2019 , 68, 1190-1199	19.2	8
149	Roux-en-Y Gastric-Bypass and sleeve gastrectomy induces specific shifts of the gut microbiota without altering the metabolism of bile acids in the intestinal lumen. <i>International Journal of Obesity</i> , 2019 , 43, 428-431	5.5	16
148	Gut microbiota: Beyond metagenomics, metatranscriptomics illuminates microbiome functionality in IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018 , 15, 193-194	24.2	23
147	Aryl hydrocarbon receptor and intestinal immunity. <i>Mucosal Immunology</i> , 2018 , 11, 1024-1038	9.2	168
146	Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 485-493	6.1	61
145	Interleukin-22-deficiency and microbiota contribute to the exacerbation of <i>Toxoplasma gondii</i> -induced intestinal inflammation. <i>Mucosal Immunology</i> , 2018 , 11, 1181-1190	9.2	17
144	Differences in epidemiological features between ulcerative colitis and Crohn's disease: The early life-programmed versus late dysbiosis hypothesis. <i>Medical Hypotheses</i> , 2018 , 115, 19-21	3.8	7
143	The microbiota: an underestimated actor in radiation-induced lesions?. <i>Gut</i> , 2018 , 67, 1-2	19.2	25
142	Features of Autoimmune Pancreatitis Associated With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 59-67	6.9	28

141	Mucosa-associated microbiota dysbiosis in colitis associated cancer. <i>Gut Microbes</i> , 2018 , 9, 131-142	8.8	83
140	Impaired Aryl Hydrocarbon Receptor Ligand Production by the Gut Microbiota Is a Key Factor in Metabolic Syndrome. <i>Cell Metabolism</i> , 2018 , 28, 737-749.e4	24.6	188
139	Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID). <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 713-722	6.1	7
138	Nucleotide-Binding Domain Leucine-Rich Repeat Containing Proteins and Intestinal Microbiota: Pivotal Players in Colitis and Colitis-Associated Cancer Development. <i>Frontiers in Immunology</i> , 2018 , 9, 1039	8.4	2
137	A Versatile New Model of Chemically Induced Chronic Colitis Using an Outbred Murine Strain. <i>Frontiers in Microbiology</i> , 2018 , 9, 565	5.7	21
136	<i>Bilophila wadsworthia</i> aggravates high fat diet induced metabolic dysfunctions in mice. <i>Nature Communications</i> , 2018 , 9, 2802	17.4	160
135	Gut Microbiota-Stimulated Innate Lymphoid Cells Support β -Defensin 14 Expression in Pancreatic Endocrine Cells, Preventing Autoimmune Diabetes. <i>Cell Metabolism</i> , 2018 , 28, 557-572.e6	24.6	67
134	Phages infecting <i>Faecalibacterium prausnitzii</i> belong to novel viral genera that help to decipher intestinal viromes. <i>Microbiome</i> , 2018 , 6, 65	16.6	57
133	Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease. <i>Cell Host and Microbe</i> , 2018 , 23, 716-724	23.4	682
132	Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population. <i>PLoS Genetics</i> , 2018 , 14, e1007329	6	41
131	Card9 mediates susceptibility to intestinal pathogens through microbiota modulation and control of bacterial virulence. <i>Gut</i> , 2018 , 67, 1836-1844	19.2	25
130	Specificities of the intestinal microbiota in patients with inflammatory bowel disease and <i>Clostridium difficile</i> infection. <i>Gut Microbes</i> , 2018 , 9, 55-60	8.8	49
129	Clinical and multi-omics cross-phenotyping of patients with autoimmune and autoinflammatory diseases: the observational TRANSIMMUNOM protocol. <i>BMJ Open</i> , 2018 , 8, e021037	3	12
128	Diet-Induced Dysbiosis and Genetic Background Synergize With Cystic Fibrosis Transmembrane Conductance Regulator Deficiency to Promote Cholangiopathy in Mice. <i>Hepatology Communications</i> , 2018 , 2, 1533-1549	6	16
127	Inhibitory Effect of Ursodeoxycholic Acid on Germination Is Insufficient to Prevent Colitis: A Study in Hamsters and Humans. <i>Frontiers in Microbiology</i> , 2018 , 9, 2849	5.7	8
126	Male gender, active smoking and previous intestinal resection are risk factors for post-operative endoscopic recurrence in Crohn's disease: results from a prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 924-932	6.1	35
125	Expression of CCR6 and CXCR6 by Gut-Derived CD4/CD8 ⁺ T-Regulatory Cells, Which Are Decreased in Blood Samples From Patients With Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2018 , 155, 1205-1217	13.3	24
124	Clinical activity is an independent risk factor of ischemic heart and cerebrovascular arterial disease in patients with inflammatory bowel disease. <i>PLoS ONE</i> , 2018 , 13, e0201991	3.7	14

123	Enterobacteriaceae are essential for the modulation of colitis severity by fungi. <i>Microbiome</i> , 2018 , 6, 152	16.6	77
122	Inter-kingdom effect on epithelial cells of the N-Acyl homoserine lactone 3-oxo-C12:2, a major quorum-sensing molecule from gut microbiota. <i>PLoS ONE</i> , 2018 , 13, e0202587	3.7	21
121	Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health. <i>Nature Medicine</i> , 2018 , 24, 1113-1120	50.5	121
120	Fungal microbiota dysbiosis in IBD. <i>Gut</i> , 2017 , 66, 1039-1048	19.2	562
119	European consensus conference on faecal microbiota transplantation in clinical practice. <i>Gut</i> , 2017 , 66, 569-580	19.2	520
118	A microbial signature for Crohn's disease. <i>Gut</i> , 2017 , 66, 813-822	19.2	409
117	<i>Clostridium difficile</i> infection in acute flares of inflammatory bowel disease: A prospective study. <i>Digestive and Liver Disease</i> , 2017 , 49, 643-646	3.3	45
116	Caspase recruitment domain 9, microbiota, and tryptophan metabolism: dangerous liaisons in inflammatory bowel diseases. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2017 , 20, 243-247 ^{3.8}	3.8	9
115	Inflammatory Bowel Diseases: How to Identify High-Risk Patients 2017 , 653-660		
114	One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 310-321	6.1	85
113	Fecal Microbiota Transplantation: Do We Need Harmonization?. <i>Clinical Infectious Diseases</i> , 2017 , 64, 1292	11.6	7
112	Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1614-1622	2.4	173
111	Chronic Granulomatous Disease in Patients Reaching Adulthood: A Nationwide Study in France. <i>Clinical Infectious Diseases</i> , 2017 , 64, 767-775	11.6	38
110	Postoperative Complications after Ileocecal Resection in Crohn's Disease: A Prospective Study From the REMIND Group. <i>American Journal of Gastroenterology</i> , 2017 , 112, 337-345	0.7	104
109	Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 1077-1084	6.1	22
108	Microbiota in digestive cancers: our new partner?. <i>Carcinogenesis</i> , 2017 , 38, 1157-1166	4.6	9
107	Using murine colitis models to analyze probiotics-host interactions. <i>FEMS Microbiology Reviews</i> , 2017 , 41, S49-S70	15.1	23
106	Probiotic Strain BL23 Prevents Colitis-Associated Colorectal Cancer. <i>Frontiers in Immunology</i> , 2017 , 8, 1553	8.4	97

105	Functional Characterization of Novel Strains Isolated from Healthy Volunteers: A Step Forward in the Use of as a Next-Generation Probiotic. <i>Frontiers in Microbiology</i> , 2017 , 8, 1226	5.7	191
104	New Insights into the Diversity of the Genus. <i>Frontiers in Microbiology</i> , 2017 , 8, 1790	5.7	30
103	Experimental colitis delays and reduces the severity of collagen-induced arthritis in mice. <i>PLoS ONE</i> , 2017 , 12, e0184624	3.7	8
102	Faecal microbiota transplantation in recurrent <i>Clostridium difficile</i> infection: Recommendations from the French Group of Faecal microbiota Transplantation. <i>Digestive and Liver Disease</i> , 2016 , 48, 242-733	4.1	41
101	Microorganisms linked to inflammatory bowel disease-associated dysbiosis differentially impact host physiology in gnotobiotic mice. <i>ISME Journal</i> , 2016 , 10, 460-77	11.9	66
100	Faecalibacterium prausnitzii A2-165 has a high capacity to induce IL-10 in human and murine dendritic cells and modulates T cell responses. <i>Scientific Reports</i> , 2016 , 6, 18507	4.9	119
99	Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models. <i>Scientific Reports</i> , 2016 , 6, 19399	4.9	48
98	Decreased tryptophan and increased kynurenine levels in mastocytosis associated with digestive symptoms. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016 , 71, 416-20	9.3	3
97	Interplay between bile acid metabolism and microbiota in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2016 , 28, 1330-40	4	70
96	Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease. <i>Gut</i> , 2016 , 65, 415-425	19.2	396
95	The presence of the anti-inflammatory protein MAM, from Faecalibacterium prausnitzii, in the intestinal ecosystem. <i>Gut</i> , 2016 , 65, 882	19.2	19
94	Fungal Dysbiosis in Mucosa-associated Microbiota of Crohn's Disease Patients. <i>Journal of Crohn's and Colitis</i> , 2016 , 10, 296-305	1.5	156
93	Identification of novel anti-inflammatory probiotic strains isolated from pulque. <i>Applied Microbiology and Biotechnology</i> , 2016 , 100, 385-396	5.7	45
92	<i>Bifidobacterium animalis</i> ssp. <i>lactis</i> CNCM-I2494 Restores Gut Barrier Permeability in Chronically Low-Grade Inflamed Mice. <i>Frontiers in Microbiology</i> , 2016 , 7, 608	5.7	34
91	Impact on Life Expectancy of Withdrawing Thiopurines in Patients with Crohn's Disease in Sustained Clinical Remission: A Lifetime Risk-Benefit Analysis. <i>PLoS ONE</i> , 2016 , 11, e0157191	3.7	11
90	Mature CD8 T-cell clonal expansion in the oral cavity and digestive tract: a severe lymphoid malignancy that mimics Crohn's disease. <i>Clinical Case Reports (discontinued)</i> , 2016 , 4, 1088-1090	0.7	0
89	Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory <i>Clostridium difficile</i> Infection in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 2402-9	4.5	106
88	Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1593-1601.e2	6.9	141

87	CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. <i>Nature Medicine</i> , 2016 , 22, 598-605	50.5	628
86	Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 1102-1113	6.1	25
85	Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. <i>Immunity</i> , 2016 , 45, 931-943	32.3	376
84	Fecal microbiota transplantation in inflammatory bowel disease: the quest for the holy grail. <i>Mucosal Immunology</i> , 2016 , 9, 1360-1365	9.2	46
83	Inflammatory bowel disease after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2015 , 50, 1365-6	4.4	3
82	Identification of metabolic signatures linked to anti-inflammatory effects of Faecalibacterium prausnitzii. <i>MBio</i> , 2015 , 6,	7.8	128
81	Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model. <i>BMC Microbiology</i> , 2015 , 15, 67	4.5	128
80	Lactobacillus rhamnosus CNCM I-3690 and the commensal bacterium Faecalibacterium prausnitzii A2-165 exhibit similar protective effects to induced barrier hyper-permeability in mice. <i>Gut Microbes</i> , 2015 , 6, 1-9	8.8	95
79	Gut fungal microbiota: the Yin and Yang of inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 656-65	4.5	70
78	Factors associated with durable response to infliximab in Crohn's disease 5 years and beyond: a multicenter international cohort. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 60-70	4.5	28
77	Changes in the Lfmann Index Values During the First Years of Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 1633-40.e3	6.9	36
76	Indoleamine 2,3-Dioxygenase Fine-Tunes Immune Homeostasis in Atherosclerosis and Colitis through Repression of Interleukin-10 Production. <i>Cell Metabolism</i> , 2015 , 22, 460-71	24.6	70
75	Targeting the Microbiome in Inflammatory Bowel Disease: Critical Evaluation of Current Concepts and Moving to New Horizons. <i>Digestive Diseases</i> , 2015 , 33 Suppl 1, 105-112	3.2	22
74	Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2015 , 9, 349-55	1.5	13
73	Letter: not the end of the role of anti-viral therapy in ulcerative colitis with cytomegalovirus reactivation - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 1247-8	6.1	
72	Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. <i>Gut</i> , 2014 , 63, 1416-23	19.2	94
71	Impact of probiotics on risk factors for cardiovascular diseases. A review. <i>Critical Reviews in Food Science and Nutrition</i> , 2014 , 54, 175-89	11.5	63
70	Prevalence and risk factors of Clostridium difficile infection in patients hospitalized for flare of inflammatory bowel disease: a retrospective assessment. <i>Digestive and Liver Disease</i> , 2014 , 46, 1086-92	3.3	31

69	Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). <i>Journal of Crohn's and Colitis</i> , 2014 , 8, 31-44	1.5	111
68	Crohn's disease of the vulva. <i>Journal of Crohn's and Colitis</i> , 2014 , 8, 563-70	1.5	58
67	Beneficial effects of exclusive enteral nutrition in Crohn's disease are not mediated by <i>Faecalibacterium prausnitzii</i> . <i>Inflammatory Bowel Diseases</i> , 2014 , 20, E18	4.5	5
66	An image-based genetic assay identifies genes in T1D susceptibility loci controlling cellular antiviral immunity in mouse. <i>PLoS ONE</i> , 2014 , 9, e108777	3.7	4
65	Effects in the use of a genetically engineered strain of <i>Lactococcus lactis</i> delivering in situ IL-10 as a therapy to treat low-grade colon inflammation. <i>Human Vaccines and Immunotherapeutics</i> , 2014 , 10, 1611-21	4.4	53
64	Bacterial protein signals are associated with Crohn's disease. <i>Gut</i> , 2014 , 63, 1566-77	19.2	67
63	Probiotics and antibiotics in IBD. <i>Digestive Diseases</i> , 2014 , 32 Suppl 1, 10-7	3.2	33
62	ImmunoChip SNP array identifies novel genetic variants conferring susceptibility to candidaemia. <i>Nature Communications</i> , 2014 , 5, 4675	17.4	62
61	CD4CD8 ⁺ lymphocytes, a novel human regulatory T cell subset induced by colonic bacteria and deficient in patients with inflammatory bowel disease. <i>PLoS Biology</i> , 2014 , 12, e1001833	9.7	78
60	The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 712-20	6.1	51
59	The commensal bacterium <i>Faecalibacterium prausnitzii</i> is protective in DNBS-induced chronic moderate and severe colitis models. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 417-30	4.5	139
58	Complications and surgery in the inflammatory bowel diseases biological era. <i>Current Opinion in Gastroenterology</i> , 2014 , 30, 378-84	3	35
57	Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 978-86	4.5	117
56	Ecology and metabolism of the beneficial intestinal commensal bacterium <i>Faecalibacterium prausnitzii</i> . <i>Gut Microbes</i> , 2014 , 5, 146-51	8.8	81
55	Impact of the diagnosis and treatment of cancer on the course of inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2014 , 8, 819-24	1.5	17
54	Card9 mediates intestinal epithelial cell restitution, T-helper 17 responses, and control of bacterial infection in mice. <i>Gastroenterology</i> , 2013 , 145, 591-601.e3	13.3	107
53	<i>Faecalibacterium prausnitzii</i> and human intestinal health. <i>Current Opinion in Microbiology</i> , 2013 , 16, 255-61	6.1	576
52	Gastrointestinal manifestations in mastocytosis: a study of 83 patients. <i>Journal of Allergy and Clinical Immunology</i> , 2013 , 132, 866-73.e1-3	11.5	47

51	Efficacy and safety of thalidomide in patients with inflammatory manifestations of chronic granulomatous disease: a retrospective case series. <i>Journal of Allergy and Clinical Immunology</i> , 2013 , 132, 997-1000.e1-4	11.5	20
50	Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. <i>Gut</i> , 2013 , 62, 531-9	19.2	422
49	Long-term outcome of patients with Crohn's disease who respond to azathioprine. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 389-94	6.9	52
48	Decreased lymphatic vessel density is associated with postoperative endoscopic recurrence in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 2084-90	4.5	38
47	Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2012 , 24, 513-20, e246-7	4	164
46	Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. <i>Genome Biology</i> , 2012 , 13, R79	18.3	1668
45	Crosstalk between the hepatologist and the cardiologist: a future place for the lithocholic acid as a coronary atheroma risk factor?. <i>Hepatology</i> , 2012 , 56, 2426	11.2	9
44	Anti-inflammatory properties of dairy lactobacilli. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 657-66	4.5	46
43	Current smoking differentially affects blood mononuclear cells from patients with Crohn's disease and ulcerative colitis: relevance to its adverse role in the disease. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 1101-11	4.5	32
42	Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 2063-71	4.5	77
41	Factors affecting outcomes in Crohn's disease over 15 years. <i>Gut</i> , 2012 , 61, 1140-5	19.2	81
40	p40phox expression regulates neutrophil recruitment and function during the resolution phase of intestinal inflammation. <i>Journal of Immunology</i> , 2012 , 189, 3631-40	5.3	41
39	Clinical, serological and genetic predictors of inflammatory bowel disease course. <i>World Journal of Gastroenterology</i> , 2012 , 18, 3806-13	5.6	64
38	How to Identify High-Risk Patients in Inflammatory Bowel Disease? 2012 , 713-725		
37	Air mass pushing the liver. <i>Digestive and Liver Disease</i> , 2011 , 43, 1025	3.3	
36	Sera from patients with Crohn's disease break bacterial lipopolysaccharide tolerance of human intestinal epithelial cells via MD-2 activity. <i>Innate Immunity</i> , 2010 , 16, 381-90	2.7	11
35	Acute cryptosporidiosis as a cause of sudden recurrence of digestive symptoms in patients with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2010 , 4, 669-70	1.5	9
34	Unilateral carotid granulomatous arteritis and Crohn's disease. <i>Revue Neurologique</i> , 2010 , 166, 542-6	3	6

33	Risk factors for neoplasia in inflammatory bowel disease patients with pancolitis. <i>American Journal of Gastroenterology</i> , 2010 , 105, 2405-11	0.7	57
32	Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. <i>Gut</i> , 2010 , 59, 1363-8	19.2	132
31	The intestinal microbiota in inflammatory bowel diseases: time to connect with the host. <i>Current Opinion in Gastroenterology</i> , 2010 , 26, 327-31	3	101
30	Intragastric administration of a superoxide dismutase-producing recombinant <i>Lactobacillus casei</i> BL23 strain attenuates DSS colitis in mice. <i>International Journal of Food Microbiology</i> , 2010 , 144, 35-41	5.8	97
29	Current smoking, not duration of remission, delays Crohn's disease relapse following azathioprine withdrawal. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 362-3	4.5	11
28	Appendicitis, not appendectomy, is protective against ulcerative colitis, both in the general population and first-degree relatives of patients with IBD. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 356-7	4.5	11
27	Body mass index and disease activity at treatment initiation: potential new predictors of response to azathioprine therapy in IBD. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 714-5	4.5	0
26	Gastrointestinal involvement and manifestations in systemic mastocytosis. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 1247-53	4.5	63
25	Crypt abscess-associated microbiota in inflammatory bowel disease and acute self-limited colitis. <i>World Journal of Gastroenterology</i> , 2010 , 16, 583-7	5.6	14
24	Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. <i>Gut</i> , 2009 , 58, 1427-36	19.2	54
23	Thalidomide as a treatment for refractory CGD colitis. <i>American Journal of Gastroenterology</i> , 2009 , 104, 1069	0.7	7
22	Single immunoglobulin infusion can reverse hemodynamic failure associated with severe <i>Clostridium difficile</i> colitis. <i>American Journal of Gastroenterology</i> , 2009 , 104, 2649-50	0.7	2
21	Plexitis as a predictive factor of early postoperative clinical recurrence in Crohn's disease. <i>Gut</i> , 2009 , 58, 1218-25	19.2	82
20	Noncolorectal malignancies in inflammatory bowel disease: more than meets the eye. <i>Digestive Diseases</i> , 2009 , 27, 375-81	3.2	18
19	Epstein-Barr virus-associated lymphoproliferation awareness in hemophagocytic syndrome complicating thiopurine treatment for Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2009 , 15, 1449-51	4.5	17
18	Effects of light smoking consumption on the clinical course of Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2009 , 15, 734-41	4.5	60
17	Low counts of <i>Faecalibacterium prausnitzii</i> in colitis microbiota. <i>Inflammatory Bowel Diseases</i> , 2009 , 15, 1183-9	4.5	822
16	Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine. <i>Alimentary Pharmacology and Therapeutics</i> , 2009 , 29, 1106-13	6.1	64

15	Toll-like receptor 2 is critical for induction of Reg3 beta expression and intestinal clearance of <i>Yersinia pseudotuberculosis</i> . <i>Gut</i> , 2009 , 58, 771-6	19.2	78
14	<i>Faecalibacterium prausnitzii</i> is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 16731-6	11.5	2742
13	Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel disease?. <i>Molecular Nutrition and Food Research</i> , 2008 , 52, 906-12	5.9	27
12	Analysis of bacterial bowel communities of IBD patients: what has it revealed?. <i>Inflammatory Bowel Diseases</i> , 2008 , 14, 858-67	4.5	163
11	Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. <i>World Journal of Gastroenterology</i> , 2008 , 14, 3497-503	5.6	71
10	Pure ileal Crohn's disease without colonic involvement after a long ileo-colonic anastomosis (Lester Martin Procedure) for Hirschsprung's disease: an argument favoring a specific sensitivity of the ileum in a subset of patients with Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2007 , 13, 243-4	4.5	7
9	Molecular comparison of dominant microbiota associated with injured versus healthy mucosa in ulcerative colitis. <i>Gut</i> , 2007 , 56, 152-4	19.2	35
8	Renal cortical necrosis related to paraneoplastic antiphospholipid syndrome. <i>American Journal of Kidney Diseases</i> , 2006 , 47, 1072-4	7.4	5
7	Temperature gradient gel electrophoresis of fecal 16S rRNA reveals active <i>Escherichia coli</i> in the microbiota of patients with ulcerative colitis. <i>Journal of Clinical Microbiology</i> , 2006 , 44, 3172-7	9.7	113
6	Specificities of the fecal microbiota in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2006 , 12, 106-11	4.5	322
5	Biopsy-proven anuric acute tubular necrosis associated with vancomycin and one dose of aminoside. <i>Nephrology Dialysis Transplantation</i> , 2004 , 19, 1921-2	4.3	15
4	The enemy from within: a prophage of <i>Roseburia intestinalis</i> systematically turns lytic in the mouse gut, driving bacterial adaptation by CRISPR spacer acquisition		2
3	Specificities of the intestinal microbiota in patients with inflammatory bowel disease and <i>Clostridium difficile</i> infection		1
2	Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population		2
1	Sequencing of over 100,000 individuals identifies multiple genes and rare variants associated with Crohn's disease susceptibility		2